pharmaceutical companies

Kobayashi Pharmaceutical, the Japanese maker at the center of a supplement contamination scandal linked to suspected deaths, is reportedly considering a buyout offer worth more than ¥500 billion. The move would mark a major turning point for the company, which has faced reputational and financial fallout since the scandal, and is drawing attention to the future ownership of the troubled firm.